Electronic monitoring of medication adherence in a 1-year clinical study of 2 dosing regimens of mesalazine for adults in remission with ulcerative colitis

Inflammatory Bowel Diseases

Volumn 20, Issue 1, 2014, Pages 82-91

  Gillespie, David ^a   Hood, Kerenza ^a   Farewell, Daniel ^a   Stenson, Rachel ^a   Probert, Christopher ^b   Hawthorne, A Barney ^c  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

Author keywords

Clinical trial; Medication adherence; MEMS; Mesalazine; Ulcerative colitis

Indexed keywords

MESALAZINE;

ADULT; ARTICLE; CLINICAL STUDY; DOSAGE SCHEDULE COMPARISON; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MEDICATION EVENT MONITORING SYSTEM; MIDDLE AGED; MONITORING; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; REMISSION; SELF REPORT; SINGLE BLIND PROCEDURE; TABLET; ULCERATIVE COLITIS;

ADMINISTRATION, ORAL; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLITIS, ULCERATIVE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; FEMALE; FOLLOW-UP STUDIES; HEALTH BEHAVIOR; HUMANS; MALE; MEDICATION ADHERENCE; MESALAMINE; MICRO-ELECTRICAL-MECHANICAL SYSTEMS; MIDDLE AGED; PATIENT COMPLIANCE; PROGNOSIS; RECURRENCE; REMISSION INDUCTION;

EID: 84893703467     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/01.MIB.0000437500.60546.2a     Document Type: Article

References (42)

1. Vermeire E, Hearnshaw H, Van Royen P, et al. Patient adherence to treatment: three decades of research. A comprehensive review. J Clin Pharm Ther. 2002;26:331-342.
2. Bangsberg DR, Perry S, Charlebois ED, et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS. 2001;15: 1181-1183.
3. Kane SV. Systematic review: adherence issues in the treatment of ulcerative colitis. Aliment Pharmacol Ther. 2006;23:577-585.
4. McDonnell PJ, Jacobs MR. Hospital admissions resulting from preventable adverse drug reactions. Ann Pharmacother. 2002;36:1331-1336.
5. Berg JS, Dischler J, Wagner DJ, et al. Medication Compliance: A Healthcare Problem. Harvey Whitney Books Company; 1993:27.
6. Aliotta SL, Vlasnik JJ, DeLor B. Enhancing adherence to long-term medical therapy: a new approach to assessing and treating patients. Adv Ther. 2004;21:214-231.
7. Nunes V, Neilson J, O'Flynn N, et al. Clinical Guidelines and Evidence Review for Medicines Adherence: Involving Patients in Decisions about Prescribed Medicines and Supporting Adherence. London, United Kingdom: National Collaborating Centre for Primary Care and Royal College of General Practitioners; 2009:364.
8. Mowat C, Cole A, Windsor A, et al. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2011;60:571-607.
9. Sutherland L, Macdonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2006;2.
10. Joint Formulary Committee. British National Formulary (Online). London, United Kingdom: BMJ Group and Pharmaceutical Press; 2013. Available at: http://www.medicinescomplete.com. Accessed March 21, 2013.
11. D'IncÀ R, Bertomoro P, Mazzocco K, et al. Risk factors for non-adherence to medication in inflammatory bowel disease patients. Aliment Pharmacol Ther. 2008;27:166-172.
12. Shale MJ, Riley SA. Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2003;18:191-198.
13. Flourié B, Hagège H, Tucat G, et al. Randomised clinical trial: once-vs. twice-daily prolonged-release mesalazine for active ulcerative colitis. Aliment Pharmacol Ther. 2013;37:767-775.
14. Gandia P, Idier I, Houin G. Is once-daily mesalazine equivalent to the currently used twice-daily regimen? A study performed in 30 healthy volunteers. J Clin Pharmacol. 2007;47:334-342.
15. Hussain FN, Ajjan RA, Kapur K, et al. Once versus divided daily dosing with delayed-release mesalazine: a study of tissue drug concentrations and standard pharmacokinetic parameters. Aliment Pharmacol Ther. 2001;15: 53-62.
16. Hawthorne AB, Stenson R, Gillespie D, et al. One-year investigator-blind randomized multicenter trial comparing asacol 2.4 g once daily with 800 mg three times daily for maintenance of remission in ulcerative colitis. Inflamm Bowel Dis. 2012;18:1885-1893.
17. Kenna LA, Labbé L, Barrett JS, et al. Modeling and simulation of adherence: approaches and applications in therapeutics. AAPS J. 2005;7: E390-E407.
18. Bland MJ, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;327:307-310.
19. Harre FE, Lee KL, Pollock BG. Regression models in clinical studies: determining relationships between predictors and response. J Natl Cancer Inst. 1988;80:1198-1202.
20. Akaike H. A new look at the statistical model identification. IEEE Transactions on Automatic Control. 1974;19:716-723.
21. IBM Corp. IBM SPSS Statistics for Windows. 20.0 ed. Armonk, NY: IBM Corp. 2011.
22. R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing, 2012.
23. Bates D, Maechler M, Bolker B, et al. lme4: linear mixed-effects models using S4 classes. R package version 0.999999-0. Available at: http:// CRAN.R-project.org/package=lme4.
24. Cramer JA, Spilker B. Patient Compliance in Medical Practice and Clinical Trials: New York, NY: Raven Press; 1991.
25. Horne R, Weinman J. Self-regulation and self-management in asthma: exploring the role of illness perceptions and treatment beliefs in explaining non-adherence to preventer medication. Psychol Health. 2002;17: 17-32.
26. Farmer KC.Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. Clin Ther. 1999;21:1074-1090.
27. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23: 1296-1310.
28. Sandborn WJ, Korzenik J, Lashner B, et al. Once-daily dosing of delayedrelease oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis. Gastroenterology. 2010;138:1286-1296.e3.
29. Eisen SA, Miller DK, Woodward RS, et al. The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med. 1990; 150:1881-1884.
30. Farup PG, Hinterleitner TA, Lukáš M, et al. Mesalazine 4 g daily given as prolonged-release granules twice daily and four times daily is at least as effective as prolonged-release tablets four times daily in patients with ulcerative colitis. Inflamm Bowel Dis. 2001;7:237-242.
31. Prantera C, Viscido A, Biancone L, et al. A new oral delivery system for 5-ASA: preliminary clinical findings for MMx. Inflamm Bowel Dis. 2005; 11:421-427.
32. Kane SV, Cohen RD, Aikens JE, et al. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol. 2001;96:2929-2933.
33. Greenley RN, Kunz JH, Biank V, et al. Identifying youth nonadherence in clinical settings: data-based recommendations for children and adolescents with inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:1254-1259. doi: 10.002/ibd.21859.
34. Saini SD, Schoenfeld P, Kaulback K, et al. Effect of medication dosing frequency on adherence in chronic diseases. Am J Manag Care. 2009;15: e22-e33.
35. Bresci G, Parisi G, Bertoni M, et al. Long-term maintenance treatment in ulcerative colitis: a 10-year follow-up. Dig Liver Dis. 2002;34:419-423.
36. Kane S, Huo D, Aikens J, et al. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med. 2003;114:39-43.
37. Lachaine J, Yen L, Beauchemin C, et al. Medication adherence and persistence in the treatment of Canadian ulcerative colitis patients: analyses with the RAMQ database. BMC Gastroenterol. 2013;13:23.
38. Kane SV, Accortt NA, Magowan S, et al. Predictors of persistence with 5-aminosalicylic acid therapy for ulcerative colitis. Aliment Pharmacol Ther. 2009;29:855-862.
39. Evon DM, Esserman DA, Bonner JE, et al. Adherence to PEG/ribavirin treatment for chronic hepatitis C: prevalence, patterns, and predictors of missed doses and nonpersistence. J Viral Hepat. 2013;20:536-549.
40. Feldman SR, Camacho FT, Krejci-Manwaring J, et al. Adherence to topical therapy increases around the time of office visits. J Am Acad Dermatol. 2007;57:81-83.
41. Modi AC, Ingerski LM, Rausch JR, et al. White coat adherence over the first year of therapy in pediatric epilepsy. J Pediatr. 2012;161:695-699.
42. Acosta FJ, Ramallo-Fariña Y, Bosch E, et al. Antipsychotic treatment dosing profile in patients with schizophrenia evaluated with electronic monitoring (MEMS®). Schizophr Res. 2013;146:196-200.